INVEST trial - Summary & Results
•
2 gostaram•664 visualizações
http://www.theheart.org/web_slides/1143267.do A study on International Verapamil SR-Trandolapril (INVEST) randomized initially to verapamil sustained-release or an atenolol-based approach, with an additional four-step strategy.
Recomendados
Mais conteúdo relacionado
Mais de theheart.org
Mais de theheart.org (20)
Último
Último (20)
INVEST trial - Summary & Results
- 1. INVEST (International Verapamil SR- Trandolapril)
- 2. INVEST (International Verapamil SR-Trandolapril) C Pepine (University of Florida College of Medicine, Gainesville) American College of Cardiology 2003 Scientific Sessions • Population and design: 22 576 hypertensive patients with coronary artery disease Randomized initially to verapamil sustained-release or an atenolol-based approach, with an additional four-step strategy Prospective randomized open design study with blinded end-point evaluation (PROBE); analysis performed based on intention to treat • Primary outcome: First occurrence of death, nonfatal stroke, or nonfatal MI
- 3. INVEST: Results • The primary outcome occurred with equal frequency between the groups • New-onset diabetes occurred less frequently in the verapamil group, with new diagnoses in 7.03% compared with 8.23% in the atenolol group (RR 0.85 [95% CI 0.77–0.95]) Primary end point at 24 months Verapamil Atenolol (n=11309), Relative risk p (n=11267) , % % (95% CI) All-cause mortality, nonfatal MI or stroke 9.93 10.17 0.98 (0.90–1.06) 0.57
- 4. INVEST: Commentary* "The study adds to the growing evidence that a multidrug strategy is best in hypertension. . . . I am a firm supporter of beta blockers, but what I think these results are telling us is that there are other treatments for hypertension and we have alternatives." - Dr Carl Pepine *All comments from INVEST trial shows equivalence of CCB and beta blocker strategies in patients with CAD and hypertension (http://www.theheart.org/article/256921.do)
- 5. Become a member of http://www.theheart.org Become a fan on Facebook: http://www.facebook.com/theheartorg Follow us on Twitter: http://www.twitter.com/theheartorg theheart.org is the leading online source of independent cardiology news. We are the top provider of news and opinions for over 100 000 physicians.